首页> 美国政府科技报告 >Development of a Novel In-Situ Telomere Length Qualification System to Address Suitability of Telomerase Inhibitor Therapy to Breast Cancer
【24h】

Development of a Novel In-Situ Telomere Length Qualification System to Address Suitability of Telomerase Inhibitor Therapy to Breast Cancer

机译:开发新的原位端粒长度鉴定系统,以解决端粒酶抑制剂治疗对乳腺癌的适应性

获取原文

摘要

The ability to predetermine therapeutic intervention times following tumor resection would be invaluable to patient well being and clinical resources. We sought to determine if we could establish a methodology where in vivo tumor telomere length could be established using in situ hybridisation as a quantitative tool. This technique would require development, validation, and application to a model system. A three dimensional technique to measure telomere length was established. This technique was applied to breast cancer derived tumor cell lines thereby establishing technique, methodology, and validity. In vivo application was established using both a readily available tissue source and tumors derived from tumorigenic breast cancer cell lines. Combining the approach to breast cancer cell lines we were then able to approximate at required times of telomerase inhibition before driving the cells into telomere- driven replicative senescence. This technique represents an important development in the ability to measure telomere length in vivo and ultimately could become appropriate for clinical application.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号